Showing results (1771-1780 of 1,873) with videos related to

Sort By:
Pageof 188
Cell Death and Differentiation|February 4, 2023
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsZilu Wang, Huimin Hu, Luuk Heitink, et al.
BMJ Global Health|February 7, 2023
Health and economic benefits of achieving contraceptive and maternal health targets in Small Island Developing States in the Pacific and CaribbeanSherrie L Kelly, Tom Walsh, Dominic Delport, et al.
Cell Death and Differentiation|December 14, 2023
Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responsesJohn E La Marca, Brandon J Aubrey, Bruce Yang, et al.
Leukemia|April 9, 2016
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cellsZ Xu, P P Sharp, Y Yao, et al.
American Journal of Human Genetics|June 19, 1998
Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndromeR Vargas-Poussou, D Feldmann, M Vollmer, et al.
The Lancet. HIV|August 11, 2020
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical modelsBritta L Jewell, Edinah Mudimu, John Stover, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosisJeffrey M Rybak, C Michael Dickens, Josie E Parker, et al.
The Lancet. HIV|December 13, 2021
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysisZoe Ward, Jack Stone, Chrissy Bishop, et al.
JAMA Neurology|October 18, 2019
Ethical Challenges of Risk, Informed Consent, and Posttrial Responsibilities in Human Research With Neural Devices: A ReviewSaskia Hendriks, Christine Grady, Khara M Ramos, et al.
British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.
Pageof 188